Clinical Trials Browser

NIH × Vincristine × Dermatologic × Clear all

Subcutaneous panniculitis-like T-cell lymphoma, Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

NCT00933985 2014-05-01

Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia

Phase 1 Terminated

22 enrolled

DermatologicLymphoidOther hematologic neoplasmSarcoma

Blast Crisis, Burkitt Lymphoma, Immunoblastic Lymphadenopathy, Leukemia, Hairy Cell, Mycosis Fungoides, Recurrence, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Dendritic Cell Sarcoma, Interdigitating, Intraocular Lymphoma

Clinical Trials

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia